BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
BTAI on Nasdaq
Shares outstanding
21,847,524
Price per share
$1.62
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
3,535,682
Total reported value
$5,662,784
% of total 13F portfolios
0%
Share change
+1,193,104
Value change
+$1,738,626
Number of holders
41
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
INTEGRATED CORE STRATEGIES (US) LLC 8.4% +64% $3,762,144 +$1,654,635 1,835,192 +79% Millennium Management LLC 31 Dec 2025
ARMISTICE CAPITAL, LLC 5% -50% $564,737 -$9,229,922 288,131 -94% Armistice Capital, LLC 31 Mar 2025

As of 31 Dec 2025, 41 institutional investors reported holding 3,535,682 shares of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI). This represents 16% of the company’s total 21,847,524 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MILLENNIUM MANAGEMENT LLC 8.4% 1,835,192 +79% 0% $2,936,307
VANGUARD GROUP INC 1.3% 292,753 +52% 0% $468,405
OAKTREE CAPITAL MANAGEMENT LP 1.1% 241,188 0% 0.01% $385,902
GEODE CAPITAL MANAGEMENT, LLC 0.94% 206,168 +65% 0% $329,873
JONES FINANCIAL COMPANIES LLLP 0.63% 137,690 +282% 0% $220,304
JANE STREET GROUP, LLC 0.58% 127,501 0% $204,002
GSA CAPITAL PARTNERS LLP 0.55% 120,102 0.02% $192,000
FMR LLC 0.41% 90,300 -55% 0% $144,480
BlackRock, Inc. 0.39% 84,396 +0.14% 0% $135,033
STATE STREET CORP 0.29% 63,218 +20% 0% $101,149
Man Group plc 0.26% 56,825 0% $90,920
Oaktree Fund Advisors, LLC 0.2% 42,913 0% 0.13% $68,660
HighTower Advisors, LLC 0.19% 41,000 +17% 0% $65,600
NORTHERN TRUST CORP 0.18% 38,370 +1.7% 0% $61,392
UBS Group AG 0.18% 38,340 -12% 0% $61,344
HRT FINANCIAL LP 0.08% 18,062 0% $28,000
TWO SIGMA SECURITIES, LLC 0.08% 17,068 0% $27,309
OSAIC HOLDINGS, INC. 0.07% 15,749 +131142% 0% $25,197
DIVERSIFY WEALTH MANAGEMENT, LLC 0.07% 15,000 0% 0% $30,750
Engineers Gate Manager LP 0.06% 12,303 0% $19,685
Portfolio Strategies, Inc. 0.06% 12,178 0% $19,485
CITIGROUP INC 0.06% 12,079 +3303% 0% $19,326
IFP Advisors, Inc 0.02% 4,370 0% 0% $6,992
WELLS FARGO & COMPANY/MN 0.02% 4,325 -73% 0% $6,920
GROUP ONE TRADING LLC 0.01% 3,185 +42% 0% $5,096

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 3,535,682 $5,662,784 +$1,738,626 $1.60 41
2025 Q3 2,342,780 $5,992,669 +$4,499,749 $2.56 35
2025 Q2 603,081 $1,090,541 +$395,829 $1.81 33
2025 Q1 378,983 $769,811 +$769,716 $2.03 31